Insuman Rapid Solostar (Insulin Human)

Insulin Human mimics the natural hormone produced by the pancreas. It binds to insulin receptors on muscle, fat and liver cells, activating a signaling cascade that moves glucose‑transport proteins to the cell surface, increasing glucose uptake, and suppresses hepatic glucose production. This combined effect reduces circulating blood sugar.

The dose of Insuman Rapid Solostar is individualized and set by the prescribing healthcare professional based on the patient’s blood‑glucose monitoring, dietary intake, and overall treatment goals. No fixed dosing regimen is provided in product information; clinicians adjust the amount to achieve optimal glycemic control.

Safety data for Insuman Rapid Solostar in pregnancy and lactation are limited. It may be used only if the potential benefits to the mother outweigh any possible risks to the fetus or infant. Healthcare providers should evaluate each case carefully and monitor blood glucose closely throughout pregnancy and while nursing.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Insuman Rapid Solostar. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details (including cold‑chain handling) and any necessary import documentation.

Insuman Rapid Solostar contains human insulin, whereas many other rapid‑acting products use insulin analogues such as insulin lispro or aspart. Human insulin has a slightly longer onset and duration compared with some analogues, but it provides comparable glucose‑lowering efficacy. Choice of product often depends on physician preference, patient response, cost considerations and availability.

Insuman Rapid Solostar must be stored at 2‑8 °C (refrigerated) and protected from light. Do not freeze the product or shake the vial vigorously. Once in use, the vial can be kept at room temperature for up to 28 days, but any unused solution should be discarded after this period to maintain potency.

The medication is administered by subcutaneous injection, typically into the abdomen, thigh, or upper arm. Patients should rotate injection sites to reduce the risk of lipodystrophy. The injection should be given shortly before meals, as directed by the prescribing clinician, and proper aseptic technique must be followed.

The most serious risks include severe hypoglycemia, which can lead to loss of consciousness or seizures, and allergic reactions ranging from rash to anaphylaxis. Patients should be educated to recognize early signs of low blood glucose and to seek immediate medical attention if a severe allergic response occurs.

Insuman Rapid Solostar should not be used by individuals with a known hypersensitivity to human insulin or any excipients in the formulation. It is also contraindicated in patients experiencing hypoglycemia at the time of administration. Clinicians should assess each patient’s medical history before initiating therapy.